Olema Pharmaceuticals (OLMA)
(Delayed Data from NSDQ)
$10.67 USD
+0.60 (5.96%)
Updated May 3, 2024 04:00 PM ET
After-Market: $10.66 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OLMA 10.67 +0.60(5.96%)
Will OLMA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for OLMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OLMA
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's Why
OLMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to Trade
Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep going
Does Olema Pharmaceuticals, Inc. (OLMA) Have the Potential to Rally 80.29% as Wall Street Analysts Expect?
Other News for OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Promising Future for Olema Pharmaceuticals with Palazestrant in Breast Cancer Treatment: A Buy Rating
Citi opens 'positive catalyst watch' on Olema Oncology into data
Olema Oncology to Participate in Upcoming Investor Conferences in May
Commit To Purchase Olema Pharmaceuticals At $5, Earn 12% Annualized Using Options